Feasibility and Efficiency of Human Bone Marrow Stromal Cell Culture with Allogeneic Platelet Lysate-Supplementation for Cell Therapy against Stroke

<div>(a) shows ELISA analysis for cell surface antigens of platelets (left: CD41, right: CD61). The broken lines indicate each mean minimum detectable dose. (b) shows the measurement of growth factors in PL samples. Each graph indicates the concentration of human PDGF-BB, TGF-<i>β</i>1, and BDNF in the 12 lots of fresh PL samples, respectively. Gray bars: single donor-derived PL (sPL); white bars: mixtures type of PL (mPL).</div>

Stem Cells International

fig1

Figure 1

Figure 1: Feasibility and Efficiency of Human Bone Marrow Stromal Cell Culture with Allogeneic Platelet Lysate-Supplementation for Cell Therapy against Stroke 

Figure 1 | Feasibility and Efficiency of Human Bone Marrow Stromal Cell Culture with Allogeneic Platelet Lysate-Supplementation for Cell Therapy against Stroke 